SEARCH

SEARCH BY CITATION

References

  • 1
    Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74108.
  • 2
    Japanese Ministry of Health, Labour and Welfare. Statistical investigation result 2005. (In Japanese.) [Cited 16 Feb 2010.] Available from URL: http://www-bm.mhlw.go.jp/toukei/saikin/hw/kanja/05syoubyo/index.html.
  • 3
    Japanese Ministry of Health, Labour and Welfare. Table database system. (In Japanese.) [Cited 16 Feb 2010.] Available from URL: http://www.mhlw.go.jp/toukei/youran/indexyk_1_2.html.
  • 4
    Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 240313.
  • 5
    Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 32705.
  • 6
    Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer 2002; 94: 90210.
  • 7
    Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 377683.
  • 8
    Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 350916.
  • 9
    Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 163945.
  • 10
    Abou-Alfa GK, Letourneau R, Harker G et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006; 24: 44417.
  • 11
    Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 394652.
  • 12
    Stathopoulos GP, Syrigos K, Aravantinos G et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006; 95: 58792.
  • 13
    Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 22127.
  • 14
    Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 14308.
  • 15
    Bramhall SR, Rosemurgy A, Brown PD et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 344755.
  • 16
    Moore M, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3296302.
  • 17
    Philip PA, Benedetti J, Fenoglio-Preiser C et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [Pca]: SWOG S0205 study. J Clin Oncol 2007; 25 (Suppl 18): 199s (Abstract LBA4509).
  • 18
    Kindler HL, Niedzwiecki D, Hollis E et al. A double-blind, placebo-controlled, randomizes phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A Preliminary Analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 2007; 25 (Suppl 18): 199s (Abstract 4508).
  • 19
    Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 22317.
  • 20
    Lynch TJ Jr, Kim ES, Eaby B et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 61021.
  • 21
    Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 523546.
  • 22
    Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003; 30: 314.
  • 23
    Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19: 610214.
  • 24
    Jost M, Gasparro FP, Jensen PJ et al. Keratinocyte apoptosis induced by ultraviolet B radiation and CD95 ligation – differential protection through epidermal growth factor receptor activation and Bcl-x(L) expression. J Invest Dermatol 2001; 116: 8606.
  • 25
    Quon H, Liu F, Cummings B. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001; 23: 14759.
  • 26
    Ueda S, Ogata S, Tsuda H et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004; 29: e18.
  • 27
    Durkin A, Bloomston PM, Rosemurgy AS et al. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg 2003; 186: 4316.
  • 28
    Moore M, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 19606.
  • 29
    Kubota K, Nishiwaki Y, Tamura T et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008; 3: 143945.
  • 30
    Dragovich T, Huberman M, Von Hoff DD et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol 2007; 60: 295303.
  • 31
    Honeywell R, Laan AC, van Groeningen CJ et al. The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 847: 14252.
  • 32
    Ling J, Fettner S, Lum BL et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 2008; 19: 20916.
  • 33
    Nakamura K, Yamaguchi T, Ishihara T et al. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006; 94: 15759.
  • 34
    Tanaka T, Ikeda M, Okusaka T et al. Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 2008; 38: 75561.
  • 35
    Tamiya A, Endo M, Shukuya T et al. Features of gemcitabine-related severe pulmonary toxicity patients with pancreatic or biliary tract cancer. Pancreas 2009; 38: 83840.
  • 36
    Bhatia S, Hanna N, Ansari R et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 2002; 38: 737.
  • 37
    Ando M, Okamoto I, Yamamoto N et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006; 24: 254956.
  • 38
    Kudoh S, Kato H, Nishiwaki N et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case–control study. Am J Respir Crit Care Med 2008; 177: 134857.
  • 39
    Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol 2006; 23: 16170.
  • 40
    Yoneda KY, Shelton DK, Beckett LA et al. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol 2007; 2: 53743.
  • 41
    Wacker B, Nagrani T, Weinberg J et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 391321.
  • 42
    Van Cutsem E, Vervenne WL, Bennouna J et al. Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. Proc ASCO Gastrointestinal Cancers Symposium, 2009 (Abstr 117). [Cited 16 Feb 2010.] Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10514.
  • 43
    Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 13344.
  • 44
    Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 28: 426875.
  • 45
    Immervoll H, Hoem D, Kugarajh K et al. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 2006; 448: 78896.
  • 46
    Lee J, Jang KT, Ki CS et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007; 109: 15619.
  • 47
    Tzeng CW, Frolov A, Frolova N et al. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 2007; 141: 4649.